Imaging prostate cancer lymph node metastases with a multimodality contrast agent
暂无分享,去创建一个
Sunkuk Kwon | Ali Azhdarinia | Holly Robinson | Eva M Sevick-Muraca | Wenyaw Chan | Roger E Price | W. Chan | E. Sevick-Muraca | Mary A Hall | Pier-Anne Lachance | Ranjani Ranganathan | Sunkuk Kwon | H. Robinson | A. Azhdarinia | Mary A. Hall | Pier-Anne Lachance | R. Price | R. Ranganathan | Holly Robinson
[1] S. Digumarthy,et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.
[2] Kai Chen,et al. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Ryan Park,et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] S. Greenfield,et al. Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.
[5] Martin G Pomper,et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.
[6] H. Moch,et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. , 2006, Gynecologic oncology.
[7] D. Grignon,et al. Elevated expression of cancer‐associated proliferating cell nuclear antigen in high‐grade prostatic intraepithelial neoplasia and prostate cancer , 2011, The Prostate.
[8] Shi Ke,et al. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. , 2007, Bioconjugate chemistry.
[9] Jennifer R. Brown,et al. Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration. , 2009, Cancer biotherapy & radiopharmaceuticals.
[10] M. Steurer,et al. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance , 2006, Journal of Clinical Pathology.
[11] Eva M. Sevick-Muraca,et al. Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats , 2010, Molecular Imaging and Biology.
[12] P. Low,et al. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. , 2009, Molecular pharmaceutics.
[13] R. Price,et al. Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent. , 2010, Translational oncology.
[14] F. Wawroschek,et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. , 2003, European urology.
[15] Philip S Low,et al. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. , 2009, Molecular pharmaceutics.
[16] C. Gondi,et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.
[17] H. Koprowski,et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. , 1984, Journal of biological response modifiers.
[18] A. Fenster,et al. Molecular Targeted Enhanced Ultrasound Imaging of Flk1 Reveals Diagnosis and Prognosis Potential in a Genetically Engineered Mouse Prostate Cancer Model , 2009, Molecular imaging.
[19] H. Daldrup-Link,et al. Optical Imaging of Cellular Immunotherapy against Prostate Cancer , 2009, Molecular imaging.
[20] H. Koprowski,et al. PHASE-I CLINICAL TRIAL OF MONOCLONAL ANTIBODY IN TREATMENT OF GASTROINTESTINAL TUMOURS , 1982, The Lancet.
[21] A. Heidenreich,et al. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.
[22] M Vasei,et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers , 2006, British Journal of Cancer.
[23] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[24] E. Bergstralh,et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. , 2007, The Journal of urology.
[25] S. Asbell,et al. Surgical staging in carcinoma of the prostate: The RTOG experience , 1985, The Prostate.
[26] G. Sauter,et al. High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.
[27] G. Holl,et al. Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[28] Eva M. Sevick-Muraca,et al. Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer , 2007, Journal of Nuclear Medicine.
[29] W. Cai,et al. In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3 , 2006 .
[30] M. Ross,et al. Lymphedema beyond breast cancer , 2010, Cancer.
[31] U. Roggenbuck,et al. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. , 2008, The Journal of urology.
[32] Anke M Hövels,et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. , 2009, Radiology.
[33] A. Wu,et al. Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors , 2008, Clinical Cancer Research.
[34] Meng Yang,et al. Real‐time whole‐body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein , 2005, The Prostate.
[35] F. Montorsi,et al. Pelvic lymph node dissection in prostate cancer. , 2009, European urology.
[36] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[37] P. Waldenberger,et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.
[38] F. Fazio,et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. , 2009, European urology.
[39] A. Wu,et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.
[40] M. Emmert-Buck,et al. Identification of EpCAM as a molecular target of prostate cancer stroma. , 2009, The American journal of pathology.
[41] W. Strohl,et al. Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. , 2007, Journal of immunological methods.
[42] A. Giuliano,et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.
[43] Sanjiv S. Gambhir,et al. Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.
[44] J. Hsieh,et al. A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection , 2011, Amino Acids.
[45] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[46] O. Gires,et al. EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.
[47] A. Haese*,et al. The presence of prostate cancer on saturation biopsy can be accurately predicted , 2010, BJU international.
[48] Guenter Janetschek,et al. Papel de la biopsia dinámica del ganglio centinela en el cáncer de próstata organoconfinado , 2007 .
[49] Martin G Pomper,et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.
[50] M. Ittmann,et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. , 2001, Cancer research.
[51] H. Miyake,et al. Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR , 2007, Clinical Cancer Research.
[52] P. Choyke,et al. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. , 2011, Seminars in nuclear medicine.
[53] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[54] H. Hricak,et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. , 2007, Radiology.
[55] H. Miyake,et al. Significance of micrometastases in prostate cancer. , 2008, Surgical oncology.
[56] P Tsipouras,et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope , 2008, British Journal of Cancer.
[57] J. Seidel,et al. N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer , 2008, Clinical Cancer Research.
[58] A. Koong,et al. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[59] A. Luebke,et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker , 2006, BMC Cancer.
[60] Stephen J Mather,et al. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.
[61] A. Haese*,et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. , 2010, European journal of cancer.
[62] M. Gertsenstein,et al. Mouse in red: Red fluorescent protein expression in mouse ES cells, embryos, and adult animals , 2004, Genesis.
[63] B. Rice,et al. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. , 2004, Molecular imaging.
[64] Milton V. Marshall,et al. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. , 2008, Radiology.
[65] B. Wollenberg,et al. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody. , 2007, Anticancer research.
[66] A. Heidenreich,et al. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. , 2007, European urology.
[67] Martin G Pomper,et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.
[68] Eun Kyoung Ryu,et al. 18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging , 2008, Journal of Nuclear Medicine.
[69] Shi Ke,et al. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. , 2005, Journal of biomedical optics.
[70] B. Delahunt,et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes , 2011, Modern Pathology.
[71] W. Bodmer,et al. USE OF TWO EPITHELIUM-SPECIFIC MONOCLONAL ANTIBODIES FOR DIAGNOSIS OF MALIGNANCY IN SEROUS EFFUSIONS , 1982, The Lancet.
[72] M. Herlyn,et al. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[73] Hao Hong,et al. Positron emission tomography imaging of prostate cancer , 2010, Amino Acids.